In vitro profiling of UCB1350883, a novel, highly selective antagonist of Bcl-2
Andrew Payne(Provo College), Colin Stubberfield(UCB Pharma (United Kingdom)), John B. Porter(Royal London Hospital), Jan Tavernier(Vlaams Instituut voor Biotechnologie), Chloe Edwards(UCB Pharma (United Kingdom)), Brian Hutchinson(Joint Global Change Research Institute), Irma Lemmens(Vlaams Instituut voor Biotechnologie), Dan Ford(Vlaams Instituut voor Biotechnologie), Clare Watkins(UCB Pharma (United Kingdom)), Jeremy L. Davis(National Institutes of Health), Ben de Candole(UCB Pharma (United Kingdom))
Molecular Cancer Therapeutics
November 1, 2007
Cited by 0
Related Papers
A Proteome-Scale Map of the Human Interactome Network
|Cell|2014|1.5k
A reference map of the human binary protein interactome
|Nature|2020|1.3k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions
|The American Journal of Surgical Pathology|2003|611
Hereditary diffuse gastric cancer: updated clinical practice guidelines
|The Lancet Oncology|2020|493